<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783549</url>
  </required_header>
  <id_info>
    <org_study_id>111596</org_study_id>
    <nct_id>NCT00783549</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.</brief_title>
  <official_title>A Study in Healthy Volunteers of Single Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Compound Alone and When Co-administered With Sitagliptin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is the first study in humans to assess the safety and tolerability of various&#xD;
      doses of GSK1292263 alone, and taken with sitigliptan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 4, 2008</start_date>
  <completion_date type="Actual">March 31, 2009</completion_date>
  <primary_completion_date type="Actual">March 31, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability parameters including adverse events, clinical laboratory, electrocardiogram, and vital signs assessments.</measure>
    <time_frame>Up to 4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters, maximum observed plasma drug concentration, time to maximum observe.</measure>
    <time_frame>Up to 4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic endpoints</measure>
    <time_frame>Up to four days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>â€¢ Pharmacokinetic parameters following a dose, with and without food, and bioavailability</measure>
    <time_frame>Up to four days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships betwen drug exposures and pharmacodynamic parameters, safety, and tolerability, as appropriate.</measure>
    <time_frame>Up to four days.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Dyslipidaemias</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 active 2 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 active 3 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 active</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>an undetermined dose of GSK1292263</intervention_name>
    <description>GSK investigational product or placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ascending dose of GSK1292263</intervention_name>
    <description>Ascending dose based on target exposures or placebo</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ascending dose of GSK1292263</intervention_name>
    <description>An ascending dose based on target exposure</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ascending dose of GSK1292263</intervention_name>
    <description>An ascending dose based on target exposures.</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ascending dose of GSK1292263</intervention_name>
    <description>An ascending dose based on target exposure</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Male or female between 18 and 55 years of age&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of non-childbearing potential&#xD;
&#xD;
          -  Male subjects must agree to use one of the contraception methods listed in the&#xD;
             protocol&#xD;
&#xD;
          -  BMI within the range 20 - 29.9 kg/m2&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with protocol&#xD;
&#xD;
          -  QTcB or QTcF &lt; 450msec.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has a positive pre-study drug/alcohol screen&#xD;
&#xD;
          -  Positive urinary cotinine levels or history or regular use of tobacco- or&#xD;
             nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia&#xD;
&#xD;
          -  Unable or unwilling to abstain from caffeine-or xanthine-containing products for 24&#xD;
             hours prior to dosing until the final post-dose assessment at each treatment level.&#xD;
&#xD;
          -  Use of illicit drugs.&#xD;
&#xD;
          -  Use of alcohol for 24 hours prior to dosing until final post-dose assessment at each&#xD;
             treatment level.&#xD;
&#xD;
          -  Consumption of red wine, oranges, grapefruit or grapefruit juice from 7 days prior to&#xD;
             the first dose of study medication until collection of the final pharmacokinetic and&#xD;
             pharmacodynamic blood samples&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening&#xD;
&#xD;
          -  A positive test for HIV antibody&#xD;
&#xD;
          -  Pregnant females as determined by positive urine hCG test at screening or prior to&#xD;
             dosing&#xD;
&#xD;
          -  Lactating females&#xD;
&#xD;
          -  Has a fasting triglyceride level &gt;400mg/dL (4.45mmol/L)&#xD;
&#xD;
          -  Has anemia defined by hemoglobin concentration &lt;11.0g/dL for males or &lt;10.0g/dL for&#xD;
             females.&#xD;
&#xD;
          -  CPK values higher than 2.5 times the upper limit of normal at screening.&#xD;
&#xD;
          -  Significant ECG abnormalities&#xD;
&#xD;
          -  abnormal vital signs as defined in the&#xD;
&#xD;
          -  History of any gastrointestinal or hepatic conditions that could impact absorption of&#xD;
             the investigational compound.&#xD;
&#xD;
          -  Family history (first or second degree relatives) with a history of hypertrophic&#xD;
             cardiomyopathy.&#xD;
&#xD;
          -  Family history of torsade de pointes or other ventricular arrhythmias.&#xD;
&#xD;
          -  Family history of unexplained sudden death.&#xD;
&#xD;
          -  Evidence of early depolarization (e.g., Wolf-Parkinson-White syndrome).&#xD;
&#xD;
          -  Has clinically significant rhythm abnormalities identified during 24-hour Screening&#xD;
             Holter assessment.&#xD;
&#xD;
          -  Subjects who have asthma or a history of asthma&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within a protocol defined period&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements within 7 days or 14 days if the drug is a potential enzyme inducer or 5&#xD;
             half-lives prior to the first dose of study medication, unless in the opinion of the&#xD;
             Investigator and GSK Medical Monitor the medication will not interfere with the study&#xD;
             procedures or compromise subject safety.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation&#xD;
&#xD;
          -  Subjects who are taking low-dose aspirin for cardiovascular prophylaxis (81mg or less)&#xD;
             are eligible to participate in the study, but the aspirin must be discontinued from&#xD;
             Screening to the Follow-up visit&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  As a result of the medical interview, physical examination, or screening&#xD;
             investigations, the investigator considers the subject unfit for the study.&#xD;
&#xD;
          -  Subject is either an immediate family member of a participating investigator, study&#xD;
             coordinator, employee of an investigator; or is a member of the staff conducting the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>October 27, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tolerability</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

